Font Size

SCREEN

Profile

Direction

Menu Style

Return to page                                                                                                               

 RSV WEBINAR SERIES                                      February 2021

 

1 February  Epidemiology and Spectrum of RSV Disease

  3pm (GMT)               Chair: Dr Natasha Halasa, Vanderbilt University Medical Center, USA

Keynote Presentation:

RSV Epidemiology in a Changing World
Chair of Paediatric Infectious Diseases and Global Health
Centre for Global Health, Usher Institute
The University of Edinburgh, UK
 
(30 min presentation - includes 5 min for Q&A)
 
 
The impact of respiratory syncytial virus (RSV) on mortality and hospitalizations in Hong Kong, 1998-2015
Xiong Qian   |   University of Hong Kong, Hong Kong      (15min)
 

Early life severe respiratory syncytial virus infection increased the risk of asthma later in life Maarten van Wijhe    |   Statens Serum Institut, Denmark     (15min)

 
The Clinical Characteristics, Severity, and Seasonality of RSV Subtypes among Hospitalized Jordanian Children
Ahmad Yanis    |    Vanderbilt University Medical Center, Nashville, USA    (15min)
 
Maternal and family social risk factors for early life respiratory syncytial virus (RSV)-related hospitalizations
Tiffany Fitzpatrick   |    Yale School of Public Health, New Haven, USA   (15min)
 
 

 

8 February  RSV Molecular Biology

 3pm (GMT)                         Chair: Prof Ultan Power, Queens University Belfast, UK

 
Keynote Presentation:
Insights into the generation and function of defective viral genomes during RSV infection
Prof Carolina Lopez
BJC Investigator / Lopez Lab
Department of Molecular Biology
Washington University School of Medicine in St. Louis, USA
 
(30 min presentation - includes 5 min for Q&A)
 
Optimized reverse genetics systems for clinical isolates of respiratory syncytial virus ON1 and BA9 strains enables rapid evaluation of naturally occurring antibody escape mutants
Martin Ludlow   |  University of Veterinary Medicine Hannover Foundation, Hannover, Germany       (15min)
 
 
Trimerization of the RSV Fusion protein leads to a high energy prefusion state, or why trimerizing is destabilizing RSV F
Johannes Langedijk   |   Janssen Vaccines & Prevention, The Netherlands       (15min) 
 
 
The respiratory syncytial virus attachment glycoprotein is altered when produced in primary human bronchial epithelial cultures, reducing its infectivity for cell lines
Tiffany King   |   The Ohio State University / Nationwide Childrens Hospital, USA         (15min)
 
An unexpected encounter: RSV-NS1 interacts with a member of the mediator complex
Tessa Van Royen   |   VIB-UGent Center for Medical Biotechnology, Ghent University, Belgium     (15min)
 
 

 

15 February  RSV Pathogenesis and Immunity

 3pm (GMT)                            Chair: Dr Lindsay Broadbent, Queens University Belfast, UK

Keynote Presentation:

An integrated view of susceptibility and resistance to RSV disease
Prof Peter Openshaw
Department of Experimental Medicine
Imperial College London, UK
 
(30 min presentation - includes 5 min for Q&A)
 
Localization of Respiratory Syncytial Virus (RSV) Antigen in Bronchiolar Epithelium
Mark Ackermann   |   LambCure LLC and Oregon State University, USA  (15min)
 
 
Influenza Virus Inhibits RSV Infection via a Two-wave Expression of IFIT Proteins
Michal Mandelboim   |   Sheba Medical Center, Ramat Gan, Israel  (15min)
 
 
Characterizing RSV Immunity on Mucosal Surfaces Following Natural Infection
Peter F. Wright   |   Geisel School of Medicine at Dartmouth, Hanover, USA   (15min)
Presented by co-author  Meave Otieno
 
Immunological impact of age in an experimental RSV challenge model in elderly humans 
Stephanie Ascough   |   Imperial College London, UK    (15min)
 
 

 

22 February  RSV Vaccines and Therapies

 3pm (GMT)                            Chair: Dr Simon B. Drysdale, St George's Hospital, London, UK

Keynote Presentation:

Update on RSV Vaccines
Dr Barney S. Graham
Deputy Director
Vaccine Research Center
National Institute of Allergy and Infectious Diseases, USA
 
(30 min presentation - includes 5 min for Q&A)
 
 
A Single-cycle Live RSV Vaccine Expressing Prefusion F Protein
Pramila Lamichhane   |   Oklahoma State University, USA       (15min)

 
Phase 1/2a Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Seropositive Toddlers Aged 12 -24 Months
Matthew Snape   |   University of Oxford, UK     (15min)
 
 
The Sensitivity of Palivizumab Cost-effectiveness in Mali to Case Fatality Estimates
 Amanda Driscoll   |   University of Maryland, Baltimore, USA    (15min)

 
The Flavonoid Cyanidin Shows Antiviral and Immunomodulatory Properties Against RSV, in Vitro and in Vivo
Carlos Bueno  |   Universidad de Buenos Aires, Argentina     (15min) 

 

 

 

Save

Save

Save

Save

Save

Save

Save

Save

Save

Save